JP2014530237A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530237A5
JP2014530237A5 JP2014535867A JP2014535867A JP2014530237A5 JP 2014530237 A5 JP2014530237 A5 JP 2014530237A5 JP 2014535867 A JP2014535867 A JP 2014535867A JP 2014535867 A JP2014535867 A JP 2014535867A JP 2014530237 A5 JP2014530237 A5 JP 2014530237A5
Authority
JP
Japan
Prior art keywords
benzothiazol
dihydroisoquinolin
ylcarbamoyl
carboxylic acid
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014535867A
Other languages
English (en)
Japanese (ja)
Other versions
JP6049738B2 (ja
JP2014530237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/059717 external-priority patent/WO2013055895A1/en
Publication of JP2014530237A publication Critical patent/JP2014530237A/ja
Publication of JP2014530237A5 publication Critical patent/JP2014530237A5/ja
Application granted granted Critical
Publication of JP6049738B2 publication Critical patent/JP6049738B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014535867A 2011-10-14 2012-10-11 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤 Expired - Fee Related JP6049738B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161547165P 2011-10-14 2011-10-14
US61/547,165 2011-10-14
CNPCT/CN2012/078372 2012-07-09
CN2012078372 2012-07-09
PCT/US2012/059717 WO2013055895A1 (en) 2011-10-14 2012-10-11 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016226799A Division JP6337068B2 (ja) 2011-10-14 2016-11-22 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤

Publications (3)

Publication Number Publication Date
JP2014530237A JP2014530237A (ja) 2014-11-17
JP2014530237A5 true JP2014530237A5 (enExample) 2015-12-03
JP6049738B2 JP6049738B2 (ja) 2016-12-21

Family

ID=47073545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014535867A Expired - Fee Related JP6049738B2 (ja) 2011-10-14 2012-10-11 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤
JP2016226799A Active JP6337068B2 (ja) 2011-10-14 2016-11-22 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016226799A Active JP6337068B2 (ja) 2011-10-14 2016-11-22 癌ならびに免疫疾患および自己免疫疾患の治療のためのアポトーシス誘発剤

Country Status (23)

Country Link
EP (2) EP3266776A1 (enExample)
JP (2) JP6049738B2 (enExample)
KR (1) KR102056587B1 (enExample)
CN (1) CN109535155B (enExample)
AR (1) AR088328A1 (enExample)
AU (2) AU2012322818A1 (enExample)
BR (1) BR112014009052B1 (enExample)
CA (1) CA2850976C (enExample)
CL (1) CL2014000922A1 (enExample)
CO (1) CO6950477A2 (enExample)
DO (1) DOP2014000074A (enExample)
EC (1) ECSP14000606A (enExample)
ES (1) ES2699966T3 (enExample)
IL (1) IL231926A (enExample)
MX (2) MX364950B (enExample)
PE (2) PE20181357A1 (enExample)
PH (1) PH12014500815B1 (enExample)
RU (1) RU2594282C2 (enExample)
SG (2) SG11201401479SA (enExample)
TW (1) TWI561521B (enExample)
UY (1) UY34381A (enExample)
WO (1) WO2013055895A1 (enExample)
ZA (1) ZA201402555B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
BR112017012342A2 (pt) * 2014-12-09 2018-02-27 Abbvie Inc compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
EP3952853A4 (en) * 2019-04-12 2023-04-12 Tonix Pharmaceuticals Holding Corp. INHIBITORS OF CD40-CD154 BINDING
KR102316961B1 (ko) * 2020-01-29 2021-10-26 프라비바이오 주식회사 면역억제제로서의 벤젠 유도체의 면역억제용 약학적 조성물
CN116761635A (zh) 2020-11-24 2023-09-15 诺华股份有限公司 Bcl-xl抑制剂抗体药物缀合物及其使用方法
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
KR20250027285A (ko) 2022-05-20 2025-02-25 노파르티스 아게 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법
CA3255993A1 (en) 2022-05-20 2023-11-23 Novartis Ag BCL-XL ANTIBODY-DRUG CONJUGATES AND ASSOCIATED METHODS OF USE
CA3256012A1 (en) 2022-05-20 2023-11-23 Les Laboratoires Servier ANTIBODY-DRUG CONJUGATES, MET INHIBITORS BCL-XL, AND THEIR METHODS OF USE
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
TW202540186A (zh) 2023-11-22 2025-10-16 瑞士商諾華公司 抗cd7抗體藥物結合物及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
UA91341C2 (ru) * 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
CA2747170C (en) * 2008-12-19 2017-07-18 Abbott Laboratories Tetrahydroisoquinoline derivatives and their uses to treat cancers and autoimmune disorders
CR20110389A (es) * 2008-12-19 2011-07-13 Abbott Lab Compuestos y métodos de uso
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑

Similar Documents

Publication Publication Date Title
JP2014530237A5 (enExample)
RU2014119254A (ru) Средства, вызывающие апоптоз, для лечения злокачественных новообразований и иммунных и аутоиммунных заболеваний
JP2014530238A5 (enExample)
CA2807620C (en) Pharmaceutically active compounds as axl inhibitors
US8815926B2 (en) Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
JP2020503299A5 (enExample)
US9365576B2 (en) Pyrrolopyrrolidinone compounds
JP2020531498A5 (enExample)
JP2021501220A5 (enExample)
AU2013365926A1 (en) Novel heterocyclic compounds as bromodomain inhibitors
CN112204027A (zh) Erk 抑制剂及其应用
JP2012528178A5 (enExample)
HRP20160539T1 (hr) Antagonisti trpv4
HRP20130106T1 (hr) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
RU2014119250A (ru) Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний
JP2010513304A5 (enExample)
JP2018510857A5 (enExample)
JP2016525076A5 (enExample)
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
US20220388964A1 (en) (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions
JP2010528995A5 (enExample)
JP2019523233A5 (enExample)
JP2010510319A5 (enExample)
IL259424A (en) History of indole converted to nitrogen as pge2 receptor modulators
JP2019508384A (ja) 5−置換2−(モルホリン−4−イル)−1,7−ナフチリジン